Short Interest in Milestone Pharmaceuticals Inc. (NASDAQ:MIST) Declines By 27.9%

Milestone Pharmaceuticals Inc. (NASDAQ:MIST - Get Free Report) saw a large decrease in short interest in the month of January. As of January 31st, there was short interest totalling 481,400 shares, a decrease of 27.9% from the January 15th total of 667,900 shares. Based on an average trading volume of 612,900 shares, the short-interest ratio is presently 0.8 days.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reiterated a "buy" rating and set a $25.00 price objective on shares of Milestone Pharmaceuticals in a research note on Monday, January 27th.

Hedge Funds Weigh In On Milestone Pharmaceuticals

Hedge funds have recently made changes to their positions in the business. Jones Financial Companies Lllp boosted its holdings in Milestone Pharmaceuticals by 1,000.0% during the fourth quarter. Jones Financial Companies Lllp now owns 11,000 shares of the company's stock worth $26,000 after buying an additional 10,000 shares in the last quarter. National Bank of Canada FI lifted its position in shares of Milestone Pharmaceuticals by 163.4% during the 4th quarter. National Bank of Canada FI now owns 18,700 shares of the company's stock valued at $44,000 after acquiring an additional 11,600 shares during the last quarter. PVG Asset Management Corp bought a new stake in shares of Milestone Pharmaceuticals during the 3rd quarter worth $46,000. Atria Investments Inc grew its holdings in shares of Milestone Pharmaceuticals by 44.4% in the 3rd quarter. Atria Investments Inc now owns 40,421 shares of the company's stock worth $61,000 after acquiring an additional 12,430 shares during the last quarter. Finally, Cubist Systematic Strategies LLC acquired a new stake in shares of Milestone Pharmaceuticals during the fourth quarter worth $73,000. Institutional investors and hedge funds own 86.18% of the company's stock.

Milestone Pharmaceuticals Price Performance

Milestone Pharmaceuticals stock traded down $0.06 during midday trading on Tuesday, hitting $2.21. The company's stock had a trading volume of 746,329 shares, compared to its average volume of 759,986. Milestone Pharmaceuticals has a 12 month low of $1.12 and a 12 month high of $2.75. The company has a quick ratio of 15.40, a current ratio of 15.40 and a debt-to-equity ratio of 2.18. The company has a market capitalization of $117.86 million, a PE ratio of -2.73 and a beta of 1.80. The stock's 50-day moving average price is $2.04 and its 200-day moving average price is $1.73.

Milestone Pharmaceuticals Company Profile

Milestone Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate.